

REMARKS

Applicants' election of Invention I, claims 1-17 in the response filed 8 November 2007, has been acknowledged. Claims 1-17 have been subject to a restriction requirement under 35 U.S.C. § 121 to a single invention as identified by the groups that follow:

- I. Claims 1-11, drawn to a method of identifying compounds that modulate Orexin receptor activity;
- II. Claims 12-14, drawn to a kit comprising cells and reagents used for the method of identifying Orexin receptor compounds;
- III. Claims 15-17, drawn to compounds identified by the method of using the Orexin receptor, and compositions thereof.

Applicants elect Group I, claims 1-11, without traverse for examination on the merits. Applicants elect Group I without traverse insofar as the groups are directed to patentably distinct inventions. Claims 1-11 are pending. Claims 12-21 are cancelled without prejudice to pursuing the cancelled subject matter in a divisional application.

Applicants respectfully request prompt examination on the merits of the elected invention. If the Examiner believes that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided. Favorable consideration and an early notice of allowance are respectfully requested.

Date: March 11, 2008

/Phillip A. Singer/
Phillip A. Singer
Registration No. 40,176

Woodcock Washburn LLP
Cira Centre
2929 Arch Street, 12th Floor
Philadelphia, PA 19104-2891
Telephone: (215) 568-3100
Facsimile: (215) 568-3439